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Abstract
Noonan syndrome with multiple lentigines (NSML) frequently manifests with hypertrophic 
cardiomyopathy (HCM). Recently, it was demonstrated that mTOR inhibition reverses HCM in 
NSML mice. We report for the first time on the effects of treatment with a rapamycin analog in an 
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infant with LS and a malignant form of HCM. In the boy, progressive HCM was diagnosed during 
the first week of life and diagnosis of NSML was established at age 20 weeks by showing a 
heterozygous Q510E mutation in the PTPN11 gene. Immunoblotting with antibodies against 
pERK, pAkt, and pS6RP in fibroblasts demonstrated reduced RAS/MAPK and enhanced Akt/
mTOR pathway activities. Because of the patient’s critical condition, everolimus therapy was 
started at age 24 weeks and continued until heart transplantation at age 36 weeks. Prior to surgery, 
heart failure improved from NYHA stage IV to II and brain natriuretic peptide values decreased 
from 9600 to <1000 pg/ml, but no reversal of cardiac hypertrophy was observed. Examination of 
the explanted heart revealed severe hypertrophy and myofiber disarray with extensive perivascular 
fibrosis. These findings provide evidence that Akt/mTOR activity is enhanced in NSML with 
HCM and suggest that rapamycin treatment could be principally feasible for infantile NSML. But 
the preliminary experiences made in this single patient indicate that therapy should start early to 
prevent irreversible cardiac remodelling.
Keywords
oonan syndrome with multiple lentigines; NSML; PTPN11; mTOR; hypertrophic 
cardiomyopathy; RASopathy
INTRODUCTION
Noonan syndrome with multiple lentigines (NSML), formerly known as LEOPARD 
syndrome, is a rare congenital multisystem disorder [Sarkozy et al., 2008]. About 90% of 
patients harbor heterozygous missense mutations in the protein tyrosine phosphatase, non-
receptor type 11 (PTPN11) gene, which encodes the SH2 domain-containing protein 
tyrosine phosphatase 2 (SHP2), an upstream and/or parallel regulator of the RAS/MAPK 
signalling cascade [Sarkozy et al., 2008; Marin et al., 2001]. Progressive cardiac conduction 
abnormalities occur in about 75% of subjects, while HCM is observed in greater than 80% 
of patients with cardiac involvement. HCM can manifest during infancy, and may be 
associated with severe left ventricular outflow tract (LVOT) obstruction. Both conduction 
anomalies and HCM can result in sudden death or ultimately heart failure [Sarkozy et al., 
2008].
PTPN11 mutations also cause approximately 50% of the allelic variant disorder Noonan 
syndrome (NS) [Tartaglia et al., 2001]. NS is more common (~1:2500) and is characterized 
by variably penetrant defects, including HCM, similar to those in NSML [Noonan, 1968; 
Sznajer et al., 2007]. However, point mutations identified in PTPN11 associated with NS are 
distinct from those related to NSML [Kontaridis et al., 2006; Gelb and Tartaglia, 2011]. 
While NS mutations behave as gain-of-function alleles with increased basal phosphatase 
activity [Keilhack et al., 2005), NSML mutations are catalytically impaired [Lauriol and 
Kontaridis, 2011]. Recent research has shown that NSML mice with mutations in PTPN11 
evoke HCM through hyperactivation of the AKT/mTOR pathway [Marin et al., 2011; Gelb 
and Tartaglia, 2011]. Moreover, Marin et al. showed that treatment of NSML mice with 
rapamycin could prevent the onset of disease when administered early as well as reverse 
HCM once established [Marin et al., 2011]. Based on the latter finding, it has been 
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concluded that mTOR inhibitors such as rapamycin can be considered for HCM treatment in 
NSML patients [Marin et al., 2011].
The aim of this study was to evaluate possible therapeutic effects of rapamycin treatment in 
an infant with NSML and rapidly progressive HCM due to a PTPN11 Q510E mutation. In 
addition, we sought to analyze the effects of this specific severe mutation in human cells, as 
the germ-line mutation is embryonically lethal in mice [Schramm et al., 2012]. To 
accomplish this, we assessed adverse events and monitored cardiac function during 
rapamycin analog treatment, investigated RAS/MAPK and AKT/mTOR signalling in mutant 
fibroblasts, and performed pathological examinations of the explanted heart.
CLINICAL REPORT
The patient is the first child of healthy unrelated German parents. Pregnancy was normal, 
and no signs of HCM were noticed during routine ultrasound examinations at 30 weeks 
gestational age and immediately prior to birth. The boy was born spontaneously at term 
without complication. Weight, length, and head circumference were all between the 10th and 
50th percentiles. A heart murmur prompted echocardiography on postnatal day 4, revealing 
marked HCM. Over the course of the next few weeks, cardiac hypertrophy worsened, and 
couplets and non-sustained runs of ventricular extrasystoles became apparent at 6 weeks of 
age. By 10 weeks, the patient was in New York Heart Association (NYHA) stage IV, with 
left-ventricular wall thickness during diastole (LVPWT) at 8.5 millimeters (mm) (normal <5 
mm, z-score 5.5) (Fig. 1A) and an interventricular septum thickness at end-diastole (IVST) 
at 9 mm (normal <6 mm, z-score 4.5). In addition, echocardiographic analysis displayed 
mitral valve insufficiency grade I, with fractional shortening reduced to 45%. The LVOT 
and right ventricular outflow tract (RVOT) gradients were 70 and 50 mm Hg, respectively.
Moreover, brain natriuretic peptide (BNP) levels, a fetal gene marker that becomes up-
regulated as a consequence of HCM, was significantly elevated at 9600 pg/ml (normal <50 
pg/ml) (Fig. 1B). Despite intensive anti-congestive treatment with propanolol, verapamil, 
furosemide, and spironolactone, cardiac hypertrophy in the patient exacerbated, and LVOT 
and RVOT obstruction increased to 100 and 70 mm Hg, respectively. Despite the presence 
of biventricular hypertrophy, unsuccessful transcatheter ablations of septal hypertrophy 
through instillation of 3 × 0.2 ml ethanol were performed in an attempt to improve left-
ventricular dysfunction, at 12 weeks and at 16 weeks of age, respectively.
Clinical examination at age 20 weeks disclosed mild facial dysmorphism (Fig. 2A), with 
absent acoustically evoked potentials, demonstrating a bilateral deafness. A RASopathy was 
suspected and genetic analysis confirmed a heterozygous missense mutation in exon 13 of 
the PTPN11 gene (c.1528C>G; p.Q510E) (Fig. 2B). The boy was listed for heart 
transplantation, but because of his highly unstable condition, an alternative potential 
therapeutic approach was sought. Since it was recently demonstrated that rapamycin could 
reverse HCM in a mouse model of NSML, we initiated a treatment strategy utilizing the 
rapamycin analog everolimus at a dose of 2mg/kg/day beginning at 24 weeks of age. 
Approval by the local ethics committee (AZ 23-05-11) and written informed consent from 
the parents were obtained prior to this therapy. Treatment with the rapamycin analog was 
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added to the ongoing medication regimen of the patient, consisting of furosemide, etacrynic 
acid, spironolactone, propanolol, verapamil, phenobarbitone, esomeprazole, and 
acetylsalicylic acid. Serum levels for everolimus were monitored throughout the time course 
and varied between 2.0-9.9 μg/l (therapeutic range 3-12 μg/l) (Fig. 1B). White blood cell 
count, creatinine, and glomerular filtration rate were within normal range over the whole 
treatment period. No respiratory tract or oral infection occurred. Immediately prior to start of 
everolimus treatment, echocardiography displayed a LVPWT of 14 mm (normal 6.0 mm, z-
score 8.5) an IVST of 12 mm (normal < 6.3 mm, z-score 7.5), LVOT obstruction (gradient 
100 mm Hg), and a thickened and deformed mitral valve, while the ejection fraction was 
mildly reduced (47%). Cardiac catheter examination revealed an elevated left atrial pressure 
(17 mmHg, normal < 10 mmHg), mitral valve insufficiency grade III, and an increased left-
ventricular enddiastolic pressure (22 mmHg, normal < 12mmHg). Continuous 
electrocardiogram monitoring revealed frequent runs of non-sustained ventricular 
extrasystoles and self-limiting episodes of supraventricular tachycardia (SVT). During 
treatment, we observed that heart failure improved to NYHA stage II and BNP values 
decreased to 950-1000 pg/ml within 3 weeks (Fig. 1B). Echocardiographically, mitral valve 
insufficiency improved to grade I-II, while the LVOT gradient decreased minimally to 90 
mm Hg. In addition, no runs of non-sustained ventricular extrasystoles were noticed and 
episodes of SVT had decreased distinctly after 3-4 weeks, although frequent multiple single 
ventricular extrasystoles were still recorded. Because of this functional improvement, one 
potential donor heart was rejected after 5 weeks of everolimus therapy. However, although 
LVPWT did not increase further during everolimus treatment, no reversal of cardiac 
hypertrophy, as measured by this parameter, was observed during a treatment period of 12 
weeks (Fig. 1A). Therefore, we decided to accept a further organ offered to the patient at 
that time. Following surgery at age 36 weeks, the boy’s cardiac function normalized. He 
developed temporary renal insufficiency due to cyclosporine A treatment following heart 
transplantation. Moreover, feeding difficulties not related to his cardiac status necessitated 
gastrostomy. Cochlear implant was performed at age 26 months. At last follow-up, at 36 
months of age, the boy was walking, but did not speak and was still being fed through a 
gastrostomy tube.
METHODS AND MATERIALS
Cardiac assessment
Severity of heart failure was expressed in NYHA classes (I = no signs, II = mild, III = 
moderate, and IV = severe) according to the classification for infants proposed by Ross and 
colleagues [Ross et al., 1992], and assessed by quantitative levels of BNP obtained from the 
patient’s serum at various time intervals. Cardiac hypertrophy was assessed by 
echocardiography using 2D-echocardiography and M-mode on a Toshiba Aplio SSA-770A 
with a 5-MHz transducer. Standard apical two- and four-chamber views were used for 
determination of LVPWT and other parameters of cardiac function. Data were related to 
normal values [Kampmann et al., 2011].
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Genetic analysis
Molecular genetic testing included the following sections of genes encoding proteins of the 
RAS/MAPK pathway, and known to be particularly associated with neonatal HCM: exons 7, 
12, and 13 of PTPN11, exons 2-5 of HRAS, and exons 7, 12, 14, and 17 of RAF1. Mutation 
analysis was carried out by PCR followed by bidirectional direct sequencing using the 
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) and a 3500xL 
Genetic Analyzer (Life Technologies).
Histopathological examinations
Tissue samples were processed using standard protocols. Five-micrometer paraffin sections 
were stained with hematoxylin and eosin (H&E), Giemsa and Masson trichrome. 
Immunohistochemistry was performed with anti-desmin (Dako, M760) and anti-SMA 
(Dako, M0851) antibodies. For electron microscopy, tissue samples were fixed in 3.9% 
glutaraldehyde, processed with a Leica EM TP tissue processor, and contrasted with a Leica 
EM AC20 instrument (Ultrastain kit). 1-2 μm thick sections of plastic-embedded tissue were 
stained with methylene blue (MB). Ultrathin sections were analyzed with an electron 
microscope (Zeiss EM 109).
Biochemical analyses
Skin fibroblasts isolated from the NSML patient and a normal (wild type) donor of the same 
age were cultured in AmnioMax C-100 medium (Invitrogen) with AmnioMax C-100 
supplement (Invitrogen). Cells were starved overnight in medium without supplement and 
then were either left unstimulated or were stimulated with 10 nmol/l insulin-like growth 
factor (IGF) or 25 ng/ml epidermal growth factor (EGF) for the indicated times. After 
protein extraction, immunoblots were performed, following the manufacturer’s directions, 
with anti-phospho-AKT, anti-phospho-ERK1/2, anti-phospho-S6RP, and their respective 
total proteins (Cell Signaling). Bands were visualized with enhanced chemiluminescence 
and quantified by densitometry using ImageJ 1.41 software (Wayne Rasband, http://
rsbweb.nih.gov/ij/). Protein expression was referred to the total amount of respective 
proteins. All analyses were performed 4-5 times. Data are presented as mean ± SEM. 
Statistical significance was determined using 1-way ANOVA or 2-way repeated measure 
ANOVA, as appropriate. If ANOVA was significant, individual differences were evaluated 
using the Bonferroni post-test. Values of P < 0.05 were considered statistically significant.
RESULTS
Pathological examination
Right ventricular endomyocardial biopsy was performed at 12 weeks of age, demonstrating 
mild interstitial myocardial fibrosis and distinct perivascular fibrosis with thickened 
arteriolar walls (Supplemental figure 1A+B). There was also mild disarray of hypertrophic 
cardiomyocytes, but no significant decrease of desmin filaments was observed 
(Supplemental figure 1C).
At explant when the patient was 36 weeks of age, the heart weighed 101 grams, 
approximately 2.5 times more than normal. Macroscopically, there was marked biventricular 
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hypertrophy (Fig. 3A). The cardiac cavities were not enlarged but the endocardium was 
somewhat thickened. During cutting, the myocardium appeared firm and had a whitish-
streaked appearance. Microscopic examination revealed perivascular fibrosis and foci of 
mild interstitial fibrosis. Cardiomyocyte size was increased and myocyte nuclei were 
enlarged. Perivascular fibrosis was associated with a marked increase in arteriolar wall 
thickness, likely due to media hyperplasia (Fig. 3B-D). In addition, desmin antibody staining 
disclosed myofiber disarray (Fig. 3E). This was corroborated by methylene blue stained 
semi-thin sections (Fig. 3F) and ultrastructural analysis (Fig. 3G), demonstrating disarray of 
myofibrils and Z-bands.
Biochemical analyses
Figure 4 summarizes the results of immunoblotting and corresponding quantification of 
fibroblast protein lysates. Baseline levels of pAKT and its downstream effector pS6RP were 
both significantly increased in Q510E cells as compared to WT. No significant differences 
in baseline, however, were observed in levels of pERK, a key downstream effector in the 
RAS/MAPK pathway, between WT and Q510E. In response to EGF stimulation, S6RP also 
showed significantly increased phosphorylation at 2 minutes of stimulation, whereas pAKT, 
pERK and the other time points in S6 were not significantly different between Q510E and 
WT cells (Supplemental Fig. 2). Similarly, with IGF stimulation, pS6RP was significantly 
increased at baseline and at 10 minutes following stimulation, although the data showed a 
trend towards all time points being increased in the Q510E as compared to WT in response 
to growth factor stimulation. No significance in response to stimulation with IGF was 
observed in pAKT or pERK between Q510E and WT cells (Supplemental Fig. 2).
DISCUSSION
In this report, we comprehensively assessed the clinical, genetic, histopathological, and 
functional characteristics of an infant with NSML and a malignant form of HCM caused by 
the PTPN11 Q510E mutation that was treated with a rapamycin analog for 12 weeks. Until 
now, only four subjects with this specific mutation have been reported. As in our patient, all 
four showed a severe biventricular, rapidly progressive HCM with neonatal or prenatal onset 
resulting in heart failure during infancy [Takahashi et al., 2005; Digilio et al. 2006; Faienza 
et al., 2009].
Mutations in several genes encoding components of the RAS/MAPK signalling pathway 
have been linked to RASopathies, disorders that include NS and NSML, but also cardio-
facio-cutaneous, neurofibromatosis and Costello syndromes [Digilio et al., 2011]. Most 
subjects with RASopathy and HCM bear mutations at specific locations in distinct genes 
(PTPN11, HRAS, RAF1), usually resulting in excess signalling through the RAS/MAPK 
cascade [Digilio et al. 2011; Gelb and Tartaglia, 2011]. Recently, however, it was shown 
that SHP2 is not only important for proper function of the RAS/MAPK cascade, but also for 
correct signal transduction via the AKT/mTOR pathway [Gelb and Tartaglia, 2011]. Marin 
et al. demonstrated that HCM in mice harboring the heterozygous PTPN11 Y279C NSML 
mutation is secondary to AKT/mTOR hyperactivity. They also found that treatment with 
rapamycin at the initial stages of HCM can completely reverse hypertrophy [Marin et al., 
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2011]. Similarly, Schramm et al. showed that HCM reversed in transgenic NSML mice 
overexpressing cardiomyocyte-specific Q510E mutant PTPN11, when treated with 
rapamycin immediately after birth [Schramm et al., 2012]. Importantly, while these data 
provided the first evidence for increased AKT/mTOR signalling in NSML, all experiments 
were performed in mice and the precise mechanistic role of the NSML mutations in humans 
remained unknown. Therefore, we conducted biochemical analyses in human Q510E mutant 
fibroblasts, which validated that NSML mutations in human patients also result in reduced 
RAS/MAPK phosphorylation and increased AKT/mTOR activity. Collectively, our data 
provide the first evidence that hyperactivation of the AKT/mTOR signalling pathway is the 
major mechanism leading to HCM in human NSML.
In our patient, the severity of heart failure assessed by NYHA stages and BNP levels 
improved markedly during everolimus therapy, suggesting that HCM in NSML patients can 
principally be treated with mTOR antagonists. However, although anticongestive 
medicaments remained unchanged during everolimus treatment, minor dosage modifications 
were performed. Therefore, it can not be excluded with certainty that improvements of 
hemodynamic factors secondary to these adaptations added to the functional amelioration of 
the cardiac status. Moreover, safety of everolimus therapy should be properly evaluated, 
since some reports indicated that loss of mTOR expression may also promote pathological 
hypertrophy and heart failure [Song et al., 2010; Shende et al., 2011]. In this single patient 
treated for a relatively short period of time, careful monitoring revealed no side effects. 
Overall, based on this preliminary experience we believe that short-term and/or low-dose 
administration of rapamycin could be beneficial in NSML patients with severe or rapidly 
progressive forms of HCM. As such, clinical trials of rapamycin and/or analogs should be 
considered for the treatment of severe NSML-associated HCM.
It is important to note, however, that despite the functional cardiac improvement after 12 
weeks of treatment, we did not observe reversal of the severe hypertrophy of this patient. 
Pathological examination of the explanted heart demonstrated irreversible cardiac 
remodelling, with myofiber disarray and marked perivascular fibrosis with arteriolar wall 
thickening. Less severe but similar signs of hypertrophic remodelling were observed in the 
initial endomyocardial biopsy at 12 weeks of age, suggesting that structural alterations in 
our patient occurred early, just after birth and before treatment had begun. Therefore, it is 
possible that everolimus therapy in this subject, who had advanced hypertrophic disease, 
was initiated too late to reverse pathological remodelling, and that earlier treatment may 
have been more successful. Moreover, the duration of treatment in this patient was relatively 
short, in comparison to the duration in NSML mouse studies (equivalent to one year in 
humans) [Marin et al., 2011; Schramm et al., 2012]. Thus, we cannot exclude the possibility 
that extended therapy beyond 12 weeks may have been more effective.
If HCM in infants with NSML is to be regarded as potentially treatable, it is important to 
include NSML in the differential diagnosis of infantile HCM. In some patients with PTPN11 
mutations, HCM has been diagnosed prenatally by ultrasound [Digilio et al. 2006]. Today, 
knowledge about the genotype/phenotype correlation in subjects with PTPN11 and other 
RAS/MAPK pathway gene defects allows rapid and cost-efficient screening for mutations 
associated with HCM [Zenker, 2011]. Since early detection is key in therapy, this should 
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enable identification of patients diagnosed prenatally or during early infancy with HCM who 
would benefit from immediate rapamycin treatment. Furthermore, to our knowledge, the 
subject described in this paper is the first with NSML to undergo successful heart 
transplantation, thereby exemplifying that this procedure represents a therapeutic option for 
NSML patients with terminal heart failure.
In conclusion, our observations provide further evidence that elevated baseline AKT/mTOR 
activity is likely to be the main mechanism underlying HCM in infantile NSML, suggest that 
rapamycin or rapamycin analog treatment is, in principle, feasible for improving cardiac 
function, and indicate that early treatment, prior to irreversible cardiac remodelling, may be 
the key to gaining the greatest benefit from this therapeutic strategy. Our experiments also 
show the feasibility of individualized therapies for patients with PTPN11 mutations and 
other defects in genes coding components of the RAS/MAPK pathway, as well as the 
potential utility of patient-derived fibroblasts for the evaluation of treatment options that can 
be most beneficial for the individual patient.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
ACKNOLEDGMENTS
The authors thank the patient’s family for their cooperation and permission to publish the data. The authors also 
thank Cornelia Dambmann and Gudrun Schmidt for their excellent technical assistance.
The work of M.I.K. is funded by National Institutes of Health Grants R01-HL102368 and R01-HL114775.
REFERENCES
Gelb BD, Tartaglia M. RAS signalling pathway mutations and hypertrophic cardiomyopathy: getting 
into and out of the thick of it. J Clin Invest. 2011; 121:844–847. [PubMed: 21339640] 
Digilio MC, Sarkozy A, Pacileo G, Limongelli G, Marino B, Dallapiccola B. PTPN11 gene mutations: 
linking the Gln510Glu mutation to the “LEOPARD syndrome phenotype”. Eur J Pediatr. 2006; 
165:803–805. [PubMed: 16733669] 
Digilio MC, Lepri F, Baban A, Dentici ML, Versacci P, Capolino R, Ferese R, De Luca A, Tartaglia 
M, Marino B, Dallapiccola B. RASopathies: Clinical diagnosis in the first year of life. Mol 
Syndromol. 2011; 1:282–289. [PubMed: 22190897] 
Faienza MF, Giordani L, Ferraris M, Bona G, Cavallo L. PTPN11 gene mutation and severe neonatal 
hypertrophic cardiomyopathy: what is the link? Pediatr Cardiol. 2009; 30:1012–1015. [PubMed: 
19582499] 
Kampmann C, Wiethoff CM, Wenzel A, Stolz G, Betancor M, Wippermann CF, Huth RG, Habermehl 
P, Knuf M, Emschermann T, Stopfkuchen H. Normal values of M mode echocardiographic 
measurements of more than 2000 healthy infants and children in central Europe. Heart. 2000; 
83:667–672. [PubMed: 10814626] 
Keilhack H, David FS, McGregor M, Cantley LC, Neel BG. Diverse biochemical properties of Shp2 
mutants. Implications for disease phenotypes. J Biol Chem. 2005; 280:30984–30993. [PubMed: 
15987685] 
Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. PTPN11 (Shp2) mutations in 
LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem. 2006; 
281:6785–6792. [PubMed: 16377799] 
Lauriol J, Kontaridis MI. PTPN11-associated mutations in the heart: has LEOPARD changed Its 
RASpots? Trends Cardiovasc Med. 2011; 21:97–104. [PubMed: 22681964] 
Hahn et al. Page 8
Am J Med Genet A. Author manuscript; available in PMC 2015 October 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Marin TM, Keith K, Davies B, Conner DA, Guha P, Kalaitzidis D, Wu X, Lauriol J, Wang B, Bauer 
M, Bronson R, Franchini KG, Neel BG, Kontaridis MI. Rapamycin reverses hypertrophic 
cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin 
Invest. 2011; 121:1026–1043. [PubMed: 21339643] 
Noonan JA. Hypertelorism with Turner phenotype. 1968. A new syndrome with associated congenital 
heart disease. Am J Dis Child. 116:373–380. [PubMed: 4386970] 
Ross RD, Bollinger RO, Pinsky VW. Grading the severity of congestive heart failure in infants. 
Pediatr Cardiol. 1992; 13:72–75. [PubMed: 1614922] 
Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008:3. doi: 
10.1186/1750-1172-3-13. [PubMed: 18271966] 
Schramm C, Fine DM, Edwards, Reeb AN, Krenz M. The PTPN11 loss-of-function mutation Q510E-
Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling. Am J Physiol Heart 
Circ Physiol. 2012; 302:H231–H243. [PubMed: 22058153] 
Shende P, Plaisance I, Morandi C, Pellieux C, Berthonneche C, Zorzato F, Krishnan J, Lerch R, Hall 
MN, Rüegg MA, Pedrazzini T, Brink M. Cardiac raptor ablation impairs adaptive hypertrophy, 
alters metabolic gene expression, and causes heart failure in mice. Circulation. 2011; 123:1073–
1082. [PubMed: 21357822] 
Song X, Kusakari Y, Xiao CY, Kinsella SD, Rosenberg MA, Scherrer-Crosbie M, Hara K, 
Rosenzweig A, Matsui T. mTOR attenuates the inflammatory response in cardiomyocytes and 
prevents cardiac dysfunction in pathological hypertrophy. Am J Physiol Cell Physiol. 2010; 
299:C1256–1266. [PubMed: 20861467] 
Sznajer Y, Keren B, Baumann C, Pereira S, Alberti C, Elion J, Cavé H, Verloes A. The spectrum of 
cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene. Pediatrics. 
2007; 119:e1325–1331. [PubMed: 17515436] 
Takahashi K, Kogaki S, Kurotobi S, Nasuno S, Ohta M, Okabe H, Wada K, Sakai N, Taniike M, 
Ozono K. A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly 
progressive hypertrophic cardiomyopathy. Eur J Pediatr. 2005; 164:497–500. [PubMed: 
15889278] 
Tartaglia M, Mehler EL, Goldberg R, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt 
I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. Mutations in 
PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 
2001; 29:465–468. [PubMed: 11704759] 
Zenker M. Clinical manifestations of mutations in RAS and related intracellular signal transduction 
factors. Curr Opin Pediatr. 2011; 23:443–451. [PubMed: 21750428] 
Hahn et al. Page 9
Am J Med Genet A. Author manuscript; available in PMC 2015 October 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
A: Left ventricular posterior wall thickness (LVPWT) and NYHA stages in relation to age. 
The black bar indicates the everolimus treatment period, black filled cycles correspond to 
single LVPWT values, and the hatched area reflects the normal range of LVPWT. Small 
arrows indicate transcatheter ablations and the large arrow marks the time point when heart 
transplantion was performed. B: Everolimus (open cycles) and BNP levels (closed cycles) in 
relation to age. The lower hatched area corresponds to the normal BNP range (<20 pg/ml) 
and the upper hatched area marks the therapeutic everolimus level range (3-12 μg/ml).
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Figure 2. 
A: Facial appearance of the patient included hypertelorism, flat nasal bridge, thick lips, and 
dysplastic low set ears. B: Electropherogram demonstrating a heterozygous C-to-G 
transition at position 1526 (arrow) in exon 13 of the PTPN11 gene in the patient (P) 
compared to the wild type (WT) sequence.
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Figure 3. 
A: Pathological examination of the explanted heart at age 36 weeks showing massive 
biventricular hypertrophy, thickened endocardium, and small ventricular cavities. B-D: 
Microscopic analysis depicting marked perivascular fibrosis and profound wall thickening 
of an arteriole (arrows). (e, g) Desmin staining, methylene blue stained semi-thin section 
(MB), and electron microscopy demonstrating disarray of myofibers and Z-bands.
Hahn et al. Page 12
Am J Med Genet A. Author manuscript; available in PMC 2015 October 08.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. 
Immunoblotting and corresponding quantification of fibroblast protein lysates with 
antibodies against pERK, pAKT and pS6RP and their respective total proteins, derived from 
Q510E mutant and wild type (WT) fibroblasts under baseline conditions, demonstrating that 
Q510E mutant cells have elevated AKT/mTOR signaling at baseline. n=4-5 independent 
experiments. Data represent the mean ± SEM; p values were derived using 2-tailed 
Student’s t test. * p<0.05 ; ns=non-signifiant.
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